IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
72 hedge funds and large institutions have $183M invested in IGM Biosciences in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 24 closing their positions.
594% more call options, than puts
Call options by funds: $222K | Put options by funds: $32K
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
0.99% less ownership
Funds ownership: 67.89% → 66.9% (-0.99%)
2% less capital invested
Capital invested by funds: $186M → $183M (-$3.46M)
9% less funds holding
Funds holding: 79 → 72 (-7)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.39M |
| 2 |
AG
Artal Group
Luxembourg
|
+$3.36M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.32M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.14M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$3.79M |
| 3 |
Millennium Management
New York
|
-$3.02M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.18M |
IGMS Hedge Fund Activity: Q4 2023 in Review
72 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2023, worth a combined $183M — down 1.9% from $186M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of IGMS and 17 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 21 added.
The largest buyer was Goldman Sachs, adding an estimated $3.39M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.14M sold.
- 72 institutional investors held IGM Biosciences (IGMS) as of Q4 2023, down from 79 in Q3 2023.
- Funds reported $183M of IGM Biosciences stock for Q4 2023, down 1.9% quarter-over-quarter.
- 17 funds opened new IGM Biosciences positions in Q4 2023 and 24 closed out, a net change of -7 holders.
- The largest IGM Biosciences buyer in Q4 2023 was Goldman Sachs, an estimated $3.39M added.
- The largest IGM Biosciences seller in Q4 2023 was Great Point Partners, an estimated $5.14M sold.
Based on aggregated 13F filings for Q4 2023.